glp-1 agonist oral agonists approved for clinical use. GLP-1 agonists are available Oral Small-Molecule GLP-1 Receptor Agonists:

References Sosne G, Qiu P, Kurpakus-Wheater M

Areas Without Adequate Human Evidence Cardiovascular safety Neurological and psychiatric effects Liver and kidney safety Effects on blood glucose in humans Effects on methylation pathways Genotoxicity Carcinogenicity Reproductive and developmental toxicity Use during pregnancy or breastfeeding Interactions with prescription medicines Interactions with supplements or research compounds Long-term exposure Product-Quality Risks Incorrect quinolinium compound Wrong substitution position Incorrect counterion Incorrect active-content calculation Residual starting materials Residual solvents Degradation products Heavy-metal or inorganic contamination Mismatched certificate of analysis Uncontrolled storage and transport Absence of published harm is not proof of safety A compound without routine regulated human exposure may generate very few formal safety reports simply because there is no organised pharmacovigilance system

Lee H-J, Lee S-H

8 , e2994 (2018)

Doctor Nicolette took time to explain everything and listened to what I wanted

& Rcker, G